Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)
Conditions
Interventions
mFOLFIRINOX
5-Fluorouracil (5-FU)
+6 more
Locations
2
United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
January 6, 2023
Primary Completion Date
August 16, 2023
Completion Date
October 13, 2023
Last Updated
December 17, 2024
NCT06423326
NCT07542041
NCT07283705
NCT07438106
NCT05005403
NCT03937453
Lead Sponsor
Kimberly Perez, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions